These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 31030944)

  • 1. ZBTB24 regulates the apoptosis of human T cells via CDCA7/TRAIL-receptor axis.
    Qin XY; Feng J; Chen G; Dou XW; Dai XQ; Dong HL; Gong FY; Xiao F; Zhao Y; Gao XM; Wang J
    Biochem Biophys Res Commun; 2019 Jun; 514(1):259-265. PubMed ID: 31030944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Converging disease genes in ICF syndrome: ZBTB24 controls expression of CDCA7 in mammals.
    Wu H; Thijssen PE; de Klerk E; Vonk KK; Wang J; den Hamer B; Aytekin C; van der Maarel SM; Daxinger L
    Hum Mol Genet; 2016 Sep; 25(18):4041-4051. PubMed ID: 27466202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expanding the mutation spectrum in ICF syndrome: Evidence for a gender bias in ICF2.
    van den Boogaard ML; Thijssen PE; Aytekin C; Licciardi F; Kıykım AA; Spossito L; Dalm VASH; Driessen GJ; Kersseboom R; de Vries F; van Ostaijen-Ten Dam MM; Ikinciogullari A; Dogu F; Oleastro M; Bailardo E; Daxinger L; Nain E; Baris S; van Tol MJD; Weemaes C; van der Maarel SM
    Clin Genet; 2017 Oct; 92(4):380-387. PubMed ID: 28128455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel iPSC-based model of ICF syndrome subtype 2 recapitulates the molecular phenotype of ZBTB24 deficiency.
    Lullo V; Cecere F; Batti S; Allegretti S; Morone B; Fioriniello S; Pisapia L; Genesio R; Della Ragione F; Giardino G; Pignata C; Riccio A; Matarazzo MR; Strazzullo M
    Front Immunol; 2024; 15():1419748. PubMed ID: 39040103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDCA7 and HELLS mutations undermine nonhomologous end joining in centromeric instability syndrome.
    Unoki M; Funabiki H; Velasco G; Francastel C; Sasaki H
    J Clin Invest; 2019 Jan; 129(1):78-92. PubMed ID: 30307408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulation of ZBTB24 hampers the G0/1- to S-phase cell-cycle transition via upregulating the expression of IRF-4 in human B cells.
    Liang J; Yan R; Chen G; Feng J; Wu WW; Ren W; Zhu C; Zhao Y; Gao XM; Wang J
    Genes Immun; 2016 Jul; 17(5):276-82. PubMed ID: 27098601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subtelomeric methylation distinguishes between subtypes of Immunodeficiency, Centromeric instability and Facial anomalies syndrome.
    Toubiana S; Velasco G; Chityat A; Kaindl AM; Hershtig N; Tzur-Gilat A; Francastel C; Selig S
    Hum Mol Genet; 2018 Oct; 27(20):3568-3581. PubMed ID: 30010917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced CD19 activity in B cells contributes to immunodeficiency in mice deficient in the ICF syndrome gene Zbtb24.
    Ying Z; Hardikar S; Plummer JB; Hamidi T; Liu B; Chen Y; Shen J; Mu Y; McBride KM; Chen T
    Cell Mol Immunol; 2023 Dec; 20(12):1487-1498. PubMed ID: 37990035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural basis of specific DNA binding by the transcription factor ZBTB24.
    Ren R; Hardikar S; Horton JR; Lu Y; Zeng Y; Singh AK; Lin K; Coletta LD; Shen J; Lin Kong CS; Hashimoto H; Zhang X; Chen T; Cheng X
    Nucleic Acids Res; 2019 Sep; 47(16):8388-8398. PubMed ID: 31226215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of ZBTB24 protein domains and motifs for heterochromatin localization and transcriptional activation.
    Aktar S; Sasaki H; Unoki M
    Genes Cells; 2019 Nov; 24(11):746-755. PubMed ID: 31561277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations in ZBTB24 are associated with immunodeficiency, centromeric instability, and facial anomalies syndrome type 2.
    de Greef JC; Wang J; Balog J; den Dunnen JT; Frants RR; Straasheijm KR; Aytekin C; van der Burg M; Duprez L; Ferster A; Gennery AR; Gimelli G; Reisli I; Schuetz C; Schulz A; Smeets DFCM; Sznajer Y; Wijmenga C; van Eggermond MC; van Ostaijen-Ten Dam MM; Lankester AC; van Tol MJD; van den Elsen PJ; Weemaes CM; van der Maarel SM
    Am J Hum Genet; 2011 Jun; 88(6):796-804. PubMed ID: 21596365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel deletion in ZBTB24 in a Lebanese family with immunodeficiency, centromeric instability, and facial anomalies syndrome type 2.
    Chouery E; Abou-Ghoch J; Corbani S; El Ali N; Korban R; Salem N; Castro C; Klayme S; Azoury-Abou Rjeily M; Khoury-Matar R; Debo G; Germanos-Haddad M; Delague V; Lefranc G; Mégarbané A
    Clin Genet; 2012 Nov; 82(5):489-93. PubMed ID: 21906047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative methylome analysis of ICF patients identifies heterochromatin loci that require ZBTB24, CDCA7 and HELLS for their methylated state.
    Velasco G; Grillo G; Touleimat N; Ferry L; Ivkovic I; Ribierre F; Deleuze JF; Chantalat S; Picard C; Francastel C
    Hum Mol Genet; 2018 Jul; 27(14):2409-2424. PubMed ID: 29659838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three novel ZBTB24 mutations identified in Japanese and Cape Verdean type 2 ICF syndrome patients.
    Nitta H; Unoki M; Ichiyanagi K; Kosho T; Shigemura T; Takahashi H; Velasco G; Francastel C; Picard C; Kubota T; Sasaki H
    J Hum Genet; 2013 Jul; 58(7):455-60. PubMed ID: 23739126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined immunodeficiency develops with age in Immunodeficiency-centromeric instability-facial anomalies syndrome 2 (ICF2).
    von Bernuth H; Ravindran E; Du H; Fröhler S; Strehl K; Krämer N; Issa-Jahns L; Amulic B; Ninnemann O; Xiao MS; Eirich K; Kölsch U; Hauptmann K; John R; Schindler D; Wahn V; Chen W; Kaindl AM
    Orphanet J Rare Dis; 2014 Oct; 9():116. PubMed ID: 25330735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of ZBTB24 impairs nonhomologous end-joining and class-switch recombination in patients with ICF syndrome.
    Helfricht A; Thijssen PE; Rother MB; Shah RG; Du L; Takada S; Rogier M; Moritz J; IJspeert H; Stoepker C; van Ostaijen-Ten Dam MM; Heyer V; Luijsterburg MS; de Groot A; Jak R; Grootaers G; Wang J; Rao P; Vertegaal ACO; van Tol MJD; Pan-Hammarström Q; Reina-San-Martin B; Shah GM; van der Burg M; van der Maarel SM; van Attikum H
    J Exp Med; 2020 Nov; 217(11):. PubMed ID: 32865561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The gene mutations and subtelomeric DNA methylation in immunodeficiency, centromeric instability and facial anomalies syndrome.
    Hu H; Chen C; Shi S; Li B; Duan S
    Autoimmunity; 2019; 52(5-6):192-198. PubMed ID: 31476899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of a mouse model of ICF syndrome reveals enhanced CD19 activation in inducing hypogammaglobulinemia.
    Ying Z; Hardikar S; Plummer JB; Hamidi T; Liu B; Chen Y; Shen J; Mu Y; McBride KM; Chen T
    bioRxiv; 2023 Mar; ():. PubMed ID: 36945532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneous clinical presentation in ICF syndrome: correlation with underlying gene defects.
    Weemaes CM; van Tol MJ; Wang J; van Ostaijen-ten Dam MM; van Eggermond MC; Thijssen PE; Aytekin C; Brunetti-Pierri N; van der Burg M; Graham Davies E; Ferster A; Furthner D; Gimelli G; Gennery A; Kloeckener-Gruissem B; Meyn S; Powell C; Reisli I; Schuetz C; Schulz A; Shugar A; van den Elsen PJ; van der Maarel SM
    Eur J Hum Genet; 2013 Nov; 21(11):1219-25. PubMed ID: 23486536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and Immunological Characterization of ICF Syndrome in Japan.
    Kamae C; Imai K; Kato T; Okano T; Honma K; Nakagawa N; Yeh TW; Noguchi E; Ohara A; Shigemura T; Takahashi H; Takakura S; Hayashi M; Honma A; Watanabe S; Shigemori T; Ohara O; Sasaki H; Kubota T; Morio T; Kanegane H; Nonoyama S
    J Clin Immunol; 2018 Nov; 38(8):927-937. PubMed ID: 30353301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.